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Abstract. Alterations of DNA mismatch repair genes,
primarily demonstrated in hereditary nonpolyposis colorectal
carcinomas, were reported to be of relevance for the
progression of several sporadic tumours. In this study, the
expression and mutations of MLH1, MSH2, PMS1 and PMS2
in a panel of thyroid tumours, including nodular hyperplasia,
follicular adenomas and carcinomas, were investigated. The
expressions of MLH1, MSH2 and PMS1 were generally higher
in malignant tumours than in benign lesions (p<0.01). This
observation can find potential diagnostic application in the
differentiation of follicular adenomas from follicullar
carcinomas of the thyroid. No point mutations in the DNA
mismatch repair genes MSH2 (exon 12, 13) and MLH1 (exon
15, 16) were found.
DNA mismatch repair has been shown to play a very
important role in the prevention of genetic instability.
The defects of this system were first described in HNPCC
(hereditary nonpolyposis colorectal carcinoma) (1-7) and
later were also demonstrated in several sporadic tumours
including melanomas, bladder cancer and breast tumours
(8-12). 
For humans, four genes, namely MLH1, MSH2, PMS1
and PMS2, are responsible for the control of DNA
mismatch repair. It is possible to immunohistochemically
investigate the expression of these genes at the protein
level. Thyroid tumours have not been investigated in terms
of the state of the DNA mismatch repair proteins.
Microsatellite instability and some LOH have been found
in thyroid carcinomas (13, 14). Accepting microsatellite
instability as the result of malfunctioning DNA mismatch
repair, a working hypothesis that some alterations of DNA
mismatch repair protein expression and eventual mutations
in DNA mismatch repair genes are found in thyroid
carcinomas can be formulated. Deletion of the short arm
of chromosome 3, including the locus of MLH1, reported
for thyroid carcinomas, was an additional argument in
favour of this hypothesis (15). The overall target of this
study was to check our working hypothesis and additionally
to judge the diagnostic relevance of DNA mismatch repair
gene expression. 
Materials and Methods
Patient cohort. The material investigated consisted of 51 nodular
hyperplasia, 32 follicular adenomas, 26 follicular carcinomas, 27
papillary carcinomas and 26 follicular variants of papillary
carcinomas. Among the patients were 129 females and 33 males,
whose age ranged between 19 and 78 years, averaging 49 years.
The patients were diagnosed at the Center of Pathology,
University of Göttingen (Germany) and Krakow (Poland) during
the years 1998-2003.
Immunohistochemistry. The following antibodies were applied to
demonstrate the expression of DNA mismatch repair genes:
a) N-20, rabbit polyclonal antibody against the epitope corresponding
to an amino acid sequence mapping at the terminus of hMSH2 of
human origin (Santa Cruz Biotechnology Inc., Heidelberg, Germany).
b) C-20, rabbit polyclonal antibody against the epitope corresponding
to an amino acid sequence mapping at the carboxy terminus of
hMLH1 of human origin (Santa Cruz Biotechnology Inc., Heidelberg,
Germany).
c) K-20, rabbit polyclonal antibody against the epitope corresponding
to an amino acid sequence mapping at the amino terminus of hPMS1
of human origin (Santa Cruz Biotechnology Inc.).
d) C-20, rabbit polyclonal antibody against the epitope corresponding
to an amino acid sequence mapping at the carboxy terminus of
hPMS2 of human origin (Santa Cruz Biotechnology Inc.).
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The immunohistochemical reactions in the paraffin-embedded
tumour tissue were carried out using the Stravigen Multilink kit
(Biogenex Laboratories, Hamburg, Germany). The histological
sections were mounted on lysine-coated slides. They were
deparaffinated using xylol and then transferred to a descending
alcohol series and rinsed with distilled water. Before incubation
with the primary antibodies, the sections were heated for 10 min
on a hot-plate (85ÆC) in citrate buffer (pH 6). Afterwards,
incubation with the primary antibodies was carried out overnight
at 4ÆC at an antibody concentration of 1:50. The histological
specimens were then rinsed with Tris buffer solution and incubated
at room temperature with link (Stravigen Multilink, Biogenex
Laboratories) for 45 min. After the detection reaction had been
performed using a label (Stravigen Multilink, Biogenex
Laboratories) in combination with chromogen fast red (Biogenex
Laboratories), the nuclei were counterstained with haematoxylin.
In the control reactions the primary antibodies were omitted. The
sections were evaluated using the CAS200 image analysis system
and the results were expressed as indices indicating the percentage
of immunolabelled cells.
PCR-analysis of MLH1 and MSH2 exons. The analysis of mutations
in MLH1 and MLH2 was performed in 30 paraffin-embedded
lesions of the thyroid (six nodular hyperplasia, six follicular
adenomas,  six follicular carcinomas, six papillary carcinomas and
six follicular variants of papillary carcinomas).
The histological material was cut into sterile Eppendorf
microfuge tubes. After washing once with xylene and twice with
ethanol (96%) to remove the xylene residue, the cells and cellular
debris were obtained by centrifugation at 500 rpm and 4ÆC. DNA
was isolated from the samples with QIAamp DNA Mini Kit
(QIAGEN, Hilden, Germany). Two hundred nanograms of
extracted DNA were used for PCR performed on the thermal cycler
model 480 (Perkin Elmer, Weiterstadt, Germany). Each PCR was
performed on a 50-Ìl mixture, in a thin-walled test tube, consisting
of 1 unit Tfl DNA polymerase, polymerase buffer (BIOzym,
Hessisch Oldendorf, Germany) and 20 ÌM of each dNTP. The
mixture was overlaid with mineral oil (Sigma, Munich, Germany).
The PCR primers were synthesized by MWG (Ebersberg, Germany)
and added at a final concentration of 40 pmol/l per assay. Standard
precautions against cross-contamination were taken.
The presence of nondegraded DNA in the samples was tested
by semi-nested PCR specific to the human ‚-globin gene. ‚-Globin
DNA was amplified using the primer pairs 5’-ATGGTGCACCTG
ACTCCTGAGG-3’ (sense 1)/5’-GCCATCACTAAAGGCACCGA
GC-3’ (anti-sense) and 5’-CTGTGGGGCAAGGTGAACG-3’
(sense 2)/ anti-sense. For amplification, test tubes were heated to
95ÆC for 7 min, followed by 40 cycles at 95ÆC for 45 sec, 60ÆC for
20 sec and 72ÆC for 1 min and a final extension at 72ÆC for 7 min.
For the second PCR run, 1-2 Ìl of the first run PCR product were
used. The PCR conditions in run one and two were identical.
Only ‚-globin-positive cases were used for nested PCR analysis
for the MLH1 and MSH2 exons. Exon 12 of MSH2 was amplified
with the help of the following primers: 5’-TTTCTGTTTTTAT
TTTTTTACAGG-3’ (forward primer), 5’-AAACGTTACCCCCA
CAAAG-3’ (reverse primer). For the analysis of exon 13 of MSH2
the following primers were applied: 5’-CTAACAATCCATTT
ATTAGTAGC-3’ (forward primer) and 5’-CATTTCTATCT
TCAAGGGACTAGGA-3’ (reverse primer). Exon 15 of MLH1
was investigated by applying the primers: 5’-ATTTGTCCCAAC
TGGTTGTATCTC-3’ (forward primer) and 5’-ACTATACAA
TACAGCAACTATCCT-3’ (reverse primer). Exon 16 of MLH1
was analyzed using the primers: 5’-GCTTGCTCCTTCATGTT
CTTG-3’ (forward primer) and 5’-CACCCGGCTGGAAATT
TTAT-3’ (reverse primer). For amplification of MLH1 exons 15
and 16 and MSH2 exons 12 and 13, test tubes were heated to 95ÆC
for 7 min, followed by 40 cycles at 95ÆC for 45 sec, 60ÆC for 20 sec
and 72ÆC for 1 min and a final extension at 72ÆC for 7 min.
For visualisation, 5 Ìl of each PCR assay were separated on a 2%
(w/v) agarose gel containing 0.5 Ìg ethidium bromide per ml. The
gel was registered by means of a CCD camera (Biometra, Göttingen,
Germany). The MSH2 and MLH1 amplification products were
purified with the QIAquick PCR Purification Kit (Qiagen). 
A total of 200 ng of isolated DNA were labelled with the
PRISM Ready Dye Deoxy Terminator Cycle Sequencing Kit
(Applied Biosystems, Weiterstadt, Germany) according to the
manufacturer’s instructions and analysed in an Applied Biosystems
DNA Sequencer (model 310). Oligonucleotides previously used for
amplification of fragments served as sequencing primers.
Statistics. The data were analysed using a statistical analysis system
(SPSS, version 7.5) on an IBM-compatible PC under Windows NT
4.0. They had been previously scanned into a spreadsheet (Microsoft
Excel 97), where they were made available to the statistics program
via an open database connectivity (ODBC) driver.
In general, all indices-related data were rank-scaled, i.e., no means
or standard deviations were calculated since the parameters
investigated are not metrical data per se. The median and other
percentiles were calculated for all parameters. Mann-Whitney U-tests
were used for comparisons between the groups. 
Results
Expression of DNA mismatch repair genes in nodular
hyperplasias of the thyroid. MLH1-positive cells were found in
16/51 nodular hyperplasias investigated. The MLH1 index did
not exceed 5%. MSH2, PMS1 and PMS2 were detected in
12/51 lesions. The median-index of all three markers did not
show any positive values. The PMS1 index reached maximally
25%, MSH2-10% and PMS2 5% (Tables I-IV) (Figure 1A).
Expression of DNA mismatch repair genes in follicular
adenomas of the thyroid. MLH1 was present in 16/32
adenomas. Its index oscillated between 0% and 20%,
reaching a median of 2%. MSH2-positive cells were found
in 20/32 tumours. The values of the MSH2 index peaked at
70% and demonstrated a median value of 5%. PMS1 and
PMS2 were positive in 7/32 and 14/32 adenomas,
respectively. The median expression of both markers did not
show any positive values. The PMS1 index reached
maximally 30% and the PMS2 index 20% (Tables I-IV)
(Figure 1B).
Expression of DNA mismatch repair genes in follicular
carcinomas of the thyroid. MLH1-positive cells were detected
in 21/26 follicular carcinomas and maximal MLH1 expression
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reached 90% of the tumour cells. MSH2 was present in all
cases investigated and its index showed high values with a
maximum of 90%. PMS1 and PMS2 were found in 8/26 and
9/26 cases, respectively, and maximal index values for both
markers reached 40% (Tables I-IV) (Figure 1C).
Expression of DNA mismatch repair genes in papillary
carcinomas of the thyroid. MLH1 was found in 13/27 cases and
the MLH1 index ranged between 0% and 90%. MSH2 was
present in 20/27 carcinomas and demonstrated highly positive
index values reaching maximally 95%. PMS1- and PMS2-
positive cells were found in 4/27 and 6/27 tumours, respectively.
The indices of both markers did not show high values and
peaked at 15% for PMS1 and 10% for PMS2 (Tables I-IV).
Expression of DNA mismatch repair genes in follicular variants
of papillary carcinomas. Nineteen out of 26 cases contained
MLH1- and PMS1-positive cells. The MLH1 index
demonstrated values between 0% and 70%. The PMS1 index
reached a maximum 60%. MSH2 was present in 14/26
carcinomas with maximal expression of 70% of tumour cells.
PMS2 was detected in 23/26 tumours and the PMS2 index
values oscillated between 0% and 40% (Tables I-IV).
Comparison of DNA mismatch repair gene expression in
nodular hyperplasias and follicular adenomas of the thyroid.
A comparison of DNA mismatch repair gene expression in
nodular hyperplasias and follicular adenomas of the thyroid
demonstrated a highly significant difference in terms of the
MSH2 expression (p<0.01) and a significant difference for
MLH1 expression (p<0.05).
Comparison of DNA mismatch repair gene expression in
follicular adenomas and carcinomas of the thyroid. Follicular
adenomas and follicular carcinomas of the thyroid differed
very significantly with respect to MSH2, MLH1 and PMS1
expression (p<0.01).
Comparison of DNA mismatch repair gene expression in follicular
carcinomas and follicular variants of papillary carcinomas of the
thyroid. A comparison of follicular carcinomas and follicular
variants of papillary carcinomas of the thyroid demonstrated
highly significant differences in MSH2 and MLH1 expressions
(p<0.01). The difference in PMS2 expression also reached the
level of significance (p<0.05).
Comparison of DNA mismatch repair gene expression in
papillary carcinomas and follicular variants of papillary
carcinomas of the thyroid. Papillary carcinomas of the
thyroid differed from their follicular variants concerning the
expression of all four genes investigated. The difference in
MSH2 and PMS2 expressions was highly significant and the
difference in MLH1 and PMS1 positivities reached the level
of significance.
Comparison of DNA mismatch repair gene expression in
minimally invasive and widely invasive follicular carcinomas
of the thyroid. The comparison of minimally invasive (n=10)
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Table I. Expression of MLH1 in tumours of the thyroid.
Diagnosis Positive Percentage of positive cells
cases minimun median maximum
Nodular hyperplasia 16/51 0.00 0.00 5.00
Follicular adenoma 16/32 0.00 2.00 20.00
Follicular cancer 21/26 0.00 50.00 90.00
Papillary cancer 13/27 0.00 15.00 90.00
Follicular variants 19/26 0.00 20.00 70.00
Table IV. Expression of PMS2 in tumours of the thyroid.
Diagnosis Positive Percentage of positive cells
cases minimun median maximum
Nodular hyperplasia 12/51 0.00 0.00 5.00
Follicular adenoma 14/32 0.00  2.00 20.00
Follicular cancer 9/26 0.00  0.00 40.00
Papillary cancer  6/27 0.00 0.00 10.00
Follicular variants 23/26  0.00 10.00 40.00
Table III. Expression of PMS1 in tumours of the thyroid.
Diagnosis Positive Percentage of positive cells
cases minimun median maximum
Nodular hyperplasia 12/51 0.00 0.00 25.00
Follicular adenoma  7/32 0.00 0.00 30.00
Follicular cancer 8/26 0.00 0.00 40.00
Papillary cancer   4/27  0.00 0.00  15.00
Follicular variants 19/26  0.00 10.00 60.00
Table II. Expression of MSH2 in tumours of the thyroid.
Diagnosis Positive Percentage of positive cells
cases minimun median maximum
Nodular hyperplasia 12/51 0.00 0.00 10.00
Follicular adenoma 20/32 0.00 5.00 70.00
Follicular cancer 26/26 0.00 4.75 90.00
Papillary cancer 20/27 0.00 30.00 95.00
Follicular variants 14/26 0.00 10.00 70.00
and widely invasive follicular carcinomas of the thyroid did
not demonstrate any significant differences with respect to
DNA mismatch repair gene expression between both groups
(p>0.05). 
Analysis of mutations in MSH2 and MLH1. The sequencing
analysis did not demonstrate any point mutations in MSH2
(exons 12 and 13) or in MLH1 (exons 15 and 16) (Figure 2).
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Figure 2. A) Sequencing analysis demonstrated a normal sequence of
exon 12 of MSH2. B) Sequencing analysis demonstrated a normal
sequence of exon 13 of MSH2. C) Sequencing analysis demonstrated a
normal sequence of exon 15 of MLH1. D) Sequencing analysis
demonstrated a normal sequence of exon 16 of MLH1. 
Figure 1. A) MLH1 immunoreactivity in nodular hyperplasia of the
thyroid (x400). B) MSH2 immunoreactivity in nodular adenoma of the
thyroid (x400).C) Expression of MLH1 in follicular carcinoma of the
thyroid (x400).
Discussion
Various research groups have tried to overcome the
limitations of aspiration cytology in diagnosing follicular
neoplasms by examining aspirates from adenomas and
carcinomas and applying cytophotometry or morphometric
methods. Unfortunately, no parameters were found which
enable a reliable pre-operative differential diagnosis
between follicular adenoma and carcinoma (16-20). 
In our study, highly significant differences between these
groups were found with respect to the expression of three
DNA mismatch repair genes, namely MLH1, MSH2 and
PMS1. All three genes investigated showed generally higher
expressions in malignant tumours than in benign lesions. 
This observation from paraffin-embedded tissues can find
practical application in diagnostic cytopathology of follicular
neoplasias of the thyroid in distinguishing between a benign
adenoma and a follicular carcinoma of the thyroid. In
histology, this distinction is based on the identification of
invasion of either the capsule or blood vessels. In cytology,
differentiation between a benign and a malignant neoplasm
is impossible. Follicular adenomas with either macro- or
normal follicular structure can not be differentiated from
nodular hyperplasia of the thyroid. Microfollicular or
trabecular adenomas can not be differentiated from
minimally invasive follicular cancer of the thyroid.
Cytological specimens from formerly mentioned lesions
contain many follicular cells, creating either follicular
formations or rarely syncytial sheets as a substitute of a
trabecular structure of a tumour. Colloid is generally not
present. Such a cellular picture, namely follicular neoplasia,
is an indication for surgical procedure. Pre-operatively, a
malignant diagnosis can be expected in 25% of such cases.
The presence of intranuclear cytoplasmic inclusions has
been noted in follicular variants of papillary carcinomas.
Occasionally, these inclusions can also be observed in
follicular adenomas and carcinomas as well as in nodular
hyperplasias after cytostatic therapy. 
The concept of oxyphilic follicular neoplasia was created
parallel to the concept of follicular neoplasia. These tumours
mainly consist of oncocytes containing broad eosinophilic
cytoplasm with granular structure. Mitochondrial hyperplasia
in these tumours is the equivalent of cytoplasmic
differentiation and is connected with decreased
immunoreactivity for thyreoglobulin. Oncocytes are
frequently multinuclear and contain hyperchromatic nuclei
with large prominent nucleoli. Intranuclear inclusions are
sometimes present. Anisocytosis and nuclear polymorphy are
often observed. Cytologically, an oxyphilic follicular
adenoma can not be differentiated from an oxyphillic
carcinoma or from an oxyphilic variant of papillary cancer,
or sometimes even from regressive changes. About 15-20%
of oxyphilic follicular neoplasias are histologically confirmed
carcinomas (16-20). In light of these described diagnostic
problems, analysis of the DNA mismatch repair gene
expression can find potential application. When insufficient
slides for immunohistochemistry are available, the levels of
RNA-transcripts for these genes can also be evaluated. An
example of such an assay was tested by our research group in
malignant melanomas (21). 
The generally higher expression of DNA mismatch repair
genes in malignant tumours than in benign lesions can be
explained by the functional activation of DNA mismatch
repair genes connected with DNA damage as a result of
malignant transformation. Disturbances in DNA mismatch
repair result in microsatellite instability and LOH reported
previously for malignant tumours of the thyroid (13-15). 
In summary, our study demonstrated the altered
expressions of MLH1, MSH2 and PMS1 in the progression
of follicullar tumours of the thyroid with potential
diagnostic applications. 
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